This cluster is noise. The post-earnings window and strong fundamentals (raised guidance, Sephience momentum) continue to support PTCT. Monitor if larger C-suite sales emerge in the next 30 days, but this filing alone carries no bearish conviction.
PTCT drugs
PTCT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 20 $71.02entry
- T+1 · 6mo ago −1.73%α −1.93% · $69.79
- T+5 · 6mo ago +0.04%α −1.76% · $71.05
- T+20 · 5mo ago +11.21%α +10.47% · $78.98
- T+60 · 3mo ago +0.96%α −4.05% · $71.70
Price Chart
How similar events traded
Executive Summary
Two insiders at PTC Therapeutics sold a combined $220K of stock shortly after a strong Q1 earnings beat and raised guidance. CEO Matthew Klein's sale is a routine tax-withholding grant (12,500 shares awarded, none sold), while General Counsel Mark Boulding exercised options and sold a portion of the resulting shares. The total dollar value is only ~0.004% of market cap, immaterial and likely driven by standard post-earnings window openings and tax-planning, not a bearish signal.
Key Financial Metrics
Key Facts
- CEO Matthew Klein: 12,500 shares granted via award ($0) on May 13; then sold 679 shares at $73.06 ($50K) on May 14, a small tax-coverage disposition.
- General Counsel Mark Boulding: exercised 5,624 options (2,812 at $0, 2,812 at $25.69) on May 15; sold 2,356 shares ($170K) open-market.
- Total insider sales value ~$220K, representing ~0.004% of PTCT's $5.8B market cap.
- Just 12 days prior, PTCT reported Q1 2026 product revenue of $226M (up 47% YoY) and raised full-year product revenue guidance to $750-$850M.
- The insider cluster occurred after a strong earnings report and within an open trading window, consistent with routine post-earnings option exercises and tax sales.
Financial Impact
Insider sales of ~$220K, negligible relative to $5.8B market cap
Risk Factors
- Translarna and Emflaza revenue continue to decline due to generic erosion and regulatory headwinds.
- Any future insider sales above ~$2M (0.03% of market cap) would be more notable, especially if from CEO or CFO.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PTCT-1779225646329 |
Track record
29 reports on PTCT
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
- Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
- Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers